Mitchell C. Posner

11.2k total citations · 1 hit paper
175 papers, 6.4k citations indexed

About

Mitchell C. Posner is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mitchell C. Posner has authored 175 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 68 papers in Surgery and 65 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mitchell C. Posner's work include Pancreatic and Hepatic Oncology Research (35 papers), Gastric Cancer Management and Outcomes (29 papers) and Esophageal Cancer Research and Treatment (29 papers). Mitchell C. Posner is often cited by papers focused on Pancreatic and Hepatic Oncology Research (35 papers), Gastric Cancer Management and Outcomes (29 papers) and Esophageal Cancer Research and Treatment (29 papers). Mitchell C. Posner collaborates with scholars based in United States, Canada and United Kingdom. Mitchell C. Posner's co-authors include Ralph R. Weichselbaum, Peter Wu, Nikolai N. Khodarev, Peter W. T. Pisters, Mark K. Ferguson, Thomas E. Darga, John Hart, Helena J. Mauceri, Vivek N. Prachand and Samuel Hellmän and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Mitchell C. Posner

171 papers receiving 6.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Medically Necessary, Time-Sensitive Procedures: Scoring System to Ethically and Efficiently Manage Resource Scarcity and Provider Risk During the COVID-19 Pandemic

2020 228 citations Peter Angelos, Mitchell C. Posner et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Mitchell C. Posner	2.9k	2.5k	2.3k	1.0k	856	175	6.4k
Charles Lu	3.1k 1.1×	2.7k 1.1×	2.5k 1.1×	1.5k 1.5×	864 1.0×	100	8.3k
Bryan M. Clary	4.5k 1.6×	2.4k 1.0×	3.5k 1.5×	1.3k 1.2×	637 0.7×	165	8.4k
Ashley E. Winkler	3.9k 1.3×	2.5k 1.0×	1.4k 0.6×	1.1k 1.1×	848 1.0×	12	7.3k
Frederick L. Greene	3.8k 1.3×	2.2k 0.9×	2.5k 1.1×	892 0.9×	1.1k 1.2×	43	6.8k
Ricard Mesı́a	4.0k 1.4×	3.0k 1.2×	2.4k 1.0×	1.6k 1.6×	702 0.8×	164	7.8k
R. Swindell	2.3k 0.8×	1.8k 0.7×	1.5k 0.6×	848 0.8×	997 1.2×	166	6.1k
Peter Venner	3.3k 1.1×	4.8k 1.9×	1.8k 0.8×	1.9k 1.9×	1.5k 1.8×	116	8.4k
Esther Bastiaannet	4.5k 1.5×	1.6k 0.6×	1.6k 0.7×	847 0.8×	1.8k 2.0×	263	6.9k
Bruce J. Roth	2.1k 0.7×	1.7k 0.7×	2.7k 1.2×	1.4k 1.4×	562 0.7×	124	5.8k
Roderich E. Schwarz	2.2k 0.7×	2.4k 0.9×	2.0k 0.9×	1.2k 1.1×	558 0.7×	184	5.7k

Countries citing papers authored by Mitchell C. Posner

Since Specialization

Citations

This map shows the geographic impact of Mitchell C. Posner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell C. Posner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell C. Posner more than expected).

Fields of papers citing papers by Mitchell C. Posner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell C. Posner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell C. Posner. The network helps show where Mitchell C. Posner may publish in the future.

Co-authorship network of co-authors of Mitchell C. Posner

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell C. Posner. A scholar is included among the top collaborators of Mitchell C. Posner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell C. Posner. Mitchell C. Posner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hameed, Meera, Narasimhan P. Agaram, Karissa Whiting, et al.. (2023). PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis. Clinical Cancer Research. 30(2). 450–461. 1 indexed citations

Liauw, Stanley L., Tianming Wu, Denise Cloutier, et al.. (2020). A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses. Journal of Gastrointestinal Oncology. 11(6). 1399–1407. 9 indexed citations

Al‐Refaie, Waddah B., Paul A. Decker, Karla V. Ballman, et al.. (2019). Comparative Age-Based Prospective Multi-Institutional Observations of 12,367 Patients Enrolled to the American College of Surgeons Oncology Group (ACOSOG) Z901101 Trials (Alliance). Annals of Surgical Oncology. 26(13). 4213–4221. 2 indexed citations

Uppal, Abhineet, Fabrice Smieliauskas, Steven B. Maron, et al.. (2019). Facilities that service economically advantaged neighborhoods perform surgical metastasectomy more often for patients with colorectal liver metastases. Cancer. 126(2). 281–292. 12 indexed citations

Wei, Alice C., Fang‐Shu Ou, Qian Shi, et al.. (2019). Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Annals of Surgical Oncology. 26(13). 4489–4497. 19 indexed citations

Pitroda, Sean P., Melinda E. Stack, Lucy Chen, et al.. (2018). JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non–small Cell Lung Cancers. Molecular Cancer Therapeutics. 17(4). 732–739. 20 indexed citations

Oshima, Go, Michael J. Bolt, Alexandre Chlenski, et al.. (2018). DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs. Cancer Research. 79(3). 650–662. 39 indexed citations

Marsh, Robert, Marina Talamonti, Marshall S. Baker, et al.. (2017). Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. Journal of Surgical Oncology. 117(3). 354–362. 26 indexed citations

Namm, Jukes P. & Mitchell C. Posner. (2016). Transhiatal Esophagectomy for Esophageal Cancer. Journal of Laparoendoscopic & Advanced Surgical Techniques. 26(10). 752–756. 2 indexed citations

10.

Jeyarajah, D. Rohan, Russell S. Berman, Majella B. Doyle, et al.. (2016). Consensus Conference on North American Training in Hepatopancreaticobiliary Surgery: A Review of the Conference and Presentation of Consensus Statements. American Journal of Transplantation. 16(4). 1086–1093. 8 indexed citations

11.

In, Haejin, Karl Y. Bilimoria, Andrew K. Stewart, et al.. (2014). Cancer Recurrence: An Important but Missing Variable in National Cancer Registries. Annals of Surgical Oncology. 21(5). 1520–1529. 75 indexed citations

12.

Lussier, Yves A., Nikolai N. Khodarev, Kelly Regan, et al.. (2013). Correction: Oligo- and Polymetastatic Progression in Lung Metastasis(es) Patients Is Associated with Specific MicroRNAs. PLoS ONE. 8(6).

13.

Picozzi, Vincent J., Ross A. Abrams, Paul A. Decker, et al.. (2010). Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b–based chemoradiation: ACOSOG Trial Z05031. Annals of Oncology. 22(2). 348–354. 76 indexed citations

14.

Grossman, Eric, Mitchell C. Posner, & Peter Angelos. (2009). Ethics education in surgical residency: Past, present, and future. Surgery. 147(1). 114–119. 20 indexed citations

15.

Posner, Mitchell C., James O. Park, Thomas E. Darga, et al.. (2005). Progression of Barrett's Metaplasia to Adenocarcinoma Is Associated with the Suppression of the Transcriptional Programs of Epidermal Differentiation. Cancer Research. 65(8). 3146–3154. 133 indexed citations

16.

Park, James O., Carlos López, Vinay Gupta, et al.. (2002). Transcriptional control of viral gene therapy by cisplatin. Journal of Clinical Investigation. 110(3). 403–410. 36 indexed citations

17.

Park, James O., Carlos López‐Jaramillo, Vinay Gupta, et al.. (2002). Transcriptional control of viral gene therapy by cisplatin. Journal of Clinical Investigation. 110(3). 403–410. 1 indexed citations

18.

Park, James O., et al.. (2002). Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Annals of Surgical Oncology. 9(5). 500–504. 26 indexed citations

19.

Posner, Mitchell C.. (1998). Profiting from Emerging Market Stocks. Scandinavian Journal of Rheumatology. 27(4). 310–2. 5 indexed citations

20.

Posner, Mitchell C. & Ernest E. Moore. (1985). Distal greater saphenous vein cutdown—Technique of choice for rapid volume resuscitation. Journal of Emergency Medicine. 3(5). 395–399. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact